Algert Global LLC Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Algert Global LLC grew its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 78.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 660,620 shares of the company's stock after purchasing an additional 289,662 shares during the quarter. Algert Global LLC owned about 0.55% of 10x Genomics worth $9,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in TXG. Signaturefd LLC raised its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares during the period. Blue Trust Inc. raised its stake in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC boosted its holdings in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in 10x Genomics in the fourth quarter valued at approximately $52,000. Finally, SRS Capital Advisors Inc. grew its stake in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after acquiring an additional 4,324 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Stock Performance

NASDAQ TXG traded up $0.24 on Friday, hitting $8.87. 7,825,567 shares of the stock traded hands, compared to its average volume of 2,323,145. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -5.84 and a beta of 1.94. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $28.25. The business's fifty day moving average is $8.95 and its two-hundred day moving average is $12.56.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of recent research reports. Morgan Stanley cut their target price on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Citigroup dropped their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. UBS Group decreased their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Barclays dropped their price target on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of "Hold" and a consensus price target of $18.62.

Insider Buying and Selling

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were purchased at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares of the company's stock, valued at $687,237.74. The trade was a 184.41 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company's stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is owned by company insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.